Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian share markets slump
Thu, 4 Apr 01:30 pm

With heavy selling in the index heavyweights, Indian share markets plunged deeper into the red in the post-noon trading session. All the sectoral indices are trading in the red with realty , IT and banking stocks being the major losers.

BSE-Sensex is down 240 points and NSE-Nifty is trading down 83 points. While BSE Mid Cap is down 1.6%, BSE Small Cap index is trading down by 1.7%. The rupee is trading at 54.6 to the US dollar.

Majority of the public sector banking stocks are trading in the red with Bank of Baroda and Punjab & Sind Bank being the biggest losers. Only Canara Bank is trading in the green. As per provisional figures released by Reserve Bank of India (RBI) , the banking industry recorded growth of 14% each in credit and deposits in FY13. These growth rates have fallen short of RBI's projections. RBI had forecast credit and deposit growth of 16% and 15%, respectively for FY13. Reportedly, loan demand was sluggish in FY13 due to economic slowdown. At the same deposit mobilization during the year was impacted as inflation-adjusted returns were negative due to high inflation.

Most of the domestic pharma stocks are trading in the red with Indoco Remedies and Strides Acrolab being the major losers. Dr Reddy's has announced the launch of the drug Zoledronic acid injectable 5mg/100mg in the US. The company had received approval for this product in March 2013 from the US Food and Drug Administration (USFDA). The drug is the generic version Reclast, a brand of Novartis. Branded sales of the said drug in the US is US$ 355 m for the period ending Feb 2013. Other than Dr Reddy's, Emcure Pharma is the other company that holds approval for this version. This seems to be a low competition opportunity for Dr Reddy's. The stock of Dr Reddy's is trading up by 2.7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian share markets slump". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 23, 2018 (Close)